Overview
Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Marketed as Mounjaro and Zepbound.
Key Specifications
| Category | Dual GIP/GLP-1 Agonist |
| FDA Status | FDA-Approved |
| Purity Benchmark | ≥98% HPLC |
| Applications | Type 2 diabetes, weight management |
Sourcing Notes
When sourcing Tirzepatide, verify the following with any supplier: batch-specific COA with HPLC purity data, LC-MS identity confirmation showing the expected molecular weight, endotoxin testing results if the material will be used for injectable formulations, and storage/stability specifications appropriate for your intended use.
For a complete guide to COA verification, see our COA Verification Guide.
Get the Korea Bridge Sourcing Protocol
Free 38-page editorial playbook on regulatory navigation, supplier diligence, and the 12-point red flag checklist for licensed peptide procurement teams.
Get the Protocol →